Acinetobacter pittii: Infections, Resistance, and Control

Acinetobacter pittii is a gram-negative bacterium increasingly recognized as a cause of serious hospital-acquired infections, including bloodstream infections, pneumonia, and wound infections. Long overshadowed by its more notorious relative Acinetobacter baumannii, A. pittii has been gaining clinical attention as improved diagnostic tools reveal it to be more common than previously thought. Although patients infected with A. pittii tend to fare better than those infected with A. baumannii, the organism carries a growing arsenal of drug-resistance genes and has a worrying ability to survive on hospital surfaces for extended periods.

Why A. pittii Was Overlooked for So Long

A. pittii belongs to a tightly knit cluster of species known as the Acinetobacter calcoaceticus-baumannii (Acb) complex. The members of this group look nearly identical under a microscope and behave similarly in standard laboratory tests, which means routine diagnostic methods in most hospitals historically lumped them together under a single label. A clinical report might say “Acinetobacter baumannii complex” without specifying which species was actually responsible. That lumping has real consequences: the species within the complex differ in how dangerous they are, how resistant they tend to be, and which antibiotics work best against them.

Separating A. pittii from A. baumannii and A. nosocomialis (the other clinically important member of the complex) requires methods that go beyond what a typical microbiology lab could do quickly. DNA-based techniques such as gene sequencing can distinguish the species, but they demand specialized equipment and turnaround times that are impractical for bedside decisions. Phenotypic identification methods available in most diagnostic laboratories are insufficient for accurately differentiating these closely related species.¹

The technology that changed this picture is MALDI-TOF mass spectrometry, a technique that identifies bacteria by reading the unique pattern of proteins on their surface. Studies have demonstrated that MALDI-TOF can correctly identify all members of the Acb complex when the instrument’s reference database includes appropriate entries for each species.² One study achieved 100% correct identification of all six Acb complex species using intact bacterial cells.³ Other approaches, including a specific type of multiplex PCR targeting the gyrB gene, have confirmed that MALDI-TOF can differentiate species that even standard gene sequencing methods struggle to tell apart.⁴ As more hospitals adopt MALDI-TOF, reports of A. pittii infections have risen, not necessarily because the organism is spreading faster but because clinicians can finally see it clearly.

How Dangerous Is A. pittii Compared to A. baumannii

The short answer: less dangerous in most cases, but far from harmless. A. baumannii is one of the most feared hospital pathogens in the world, and A. pittii consistently shows lower mortality rates in head-to-head comparisons. In a large study of bloodstream infections, the overall mortality for A. baumannii bacteremia was about 37%, compared to roughly 13% for A. pittii.⁵ Patients infected with A. pittii also had lower 30-day mortality than those infected with either carbapenem-susceptible or carbapenem-resistant A. baumannii in another study.⁶

That survival advantage seems to stem from genuine biological differences in virulence rather than just patient selection. Research using Galleria mellonella larvae (a standard insect model for testing bacterial virulence) showed that larvae infected with A. pittii survived at significantly higher rates than those infected with A. baumannii, whether the A. baumannii strain was carbapenem-susceptible or resistant.⁶ The researchers concluded that there are intrinsic differences in virulence between A. pittii and A. baumannii.

Still, the clinical picture is not uniformly reassuring. A. baumannii bacteremia is more closely tied to ICU stays, mechanical ventilation, and drug resistance, while non-baumannii species like A. pittii are more likely to cause primary bacteremia (bloodstream infection without an obvious secondary source such as pneumonia).⁷ That means A. pittii infections sometimes appear in patients who are less critically ill to begin with, which partly contributes to the better survival numbers. The organism is less virulent overall, but it can still kill.

Virulence Traits and Hospital Survival

One of the most concerning features of A. pittii is its resilience on dry surfaces. Hospitals work hard to disinfect bed rails, ventilators, and monitors, but A. pittii can survive prolonged desiccation and then bounce back. A study found that after long-term drying, all tested A. pittii strains retained their ability to form biofilms once rehydrated with nutrient media, and some strains actually formed more biofilm after desiccation than before.⁸ Biofilms are structured communities of bacteria coated in a protective slime layer that makes them harder to kill with disinfectants and antibiotics alike. The ability to re-form a biofilm almost immediately after rehydration means that a contaminated surface that seems clean may harbor viable A. pittii waiting for a patient.

Genomic studies have cataloged the specific virulence tools A. pittii carries. An analysis of six multidrug-resistant isolates found nine virulence-associated genes present in all of them, covering functions from biofilm formation and surface adhesion to iron acquisition (which helps bacteria scavenge nutrients from the host) and motility.⁹ Interestingly, while some isolates showed high motility, others produced less biofilm than a reference strain, underscoring that A. pittii populations are not uniform. The clinical behavior you see depends on which strain is causing the infection.

How A. pittii Becomes Drug Resistant

Drug resistance in A. pittii follows some of the same playbook as A. baumannii, but with its own twists. The resistance genes most clinicians worry about are those encoding carbapenemases, enzymes that chew through carbapenems, which are often the last-resort antibiotics for gram-negative infections. In A. pittii, the most commonly reported carbapenemases belong to the OXA family, particularly OXA-58, OXA-72, and OXA-23.

A genomic study of multidrug-resistant A. pittii isolates found that all carried at least two genes for breaking down beta-lactam antibiotics, including a variant of the ampC cephalosporinase and an OXA-type enzyme. One isolate carried three different OXA genes (OXA-272, OXA-255, and OXA-72) and was the only one to display frank carbapenem resistance. All six isolates also harbored genes for quinolone resistance and efflux pumps that actively pump antibiotics out of the cell, plus a gene linked to colistin resistance.¹⁰

What makes the resistance picture especially worrying is that a large share of A. pittii’s resistance and virulence genes sit on the accessory genome rather than the core genome. A large-scale analysis of 384 A. pittii genomes from 32 countries found that the core genome accounts for only about 25 to 36% of any individual isolate’s total gene content, with antibiotic resistance and virulence genes overwhelmingly belonging to the variable, accessory portion.¹¹ In practical terms, this means the organism’s danger level can change rapidly as it picks up or loses mobile genetic elements.

A. pittii as a Resistance Gene Reservoir

Perhaps the most underappreciated role of A. pittii in hospital microbiology is not the infections it causes directly but the resistance genes it can pass to other bacteria. Carbapenemase genes in A. pittii frequently sit on plasmids, which are small, mobile pieces of DNA that can transfer between bacterial cells. A study from China characterized A. pittii strains carrying plasmid-borne OXA-58 and OXA-72 genes and concluded that these organisms may serve as an important reservoir of carbapenemase genes, with mobile genetic elements playing a key role in shuffling resistance genes and driving plasmid evolution.¹²

Even more striking, researchers identified the first conjugative plasmid in A. pittii carrying a carbapenem resistance gene. This plasmid, called pLS488, contains the full genetic machinery needed to transfer itself from one bacterium to another through direct cell-to-cell contact. In laboratory experiments, the plasmid successfully transferred OXA-23 from A. pittii into A. baumannii, conferring high-level carbapenem resistance to the recipient with minimum inhibitory concentrations above 32 mg/L.¹³ In other words, A. pittii can arm A. baumannii with carbapenem resistance. That transfer could turn an already dangerous hospital pathogen into an essentially untreatable one. This finding reframes A. pittii from a secondary player to a potential amplifier of resistance in the broader hospital ecosystem.

Where A. pittii Infections Come From

Most A. pittii infections are hospital-acquired. The classic patient is someone already in the ICU or on a general ward with indwelling catheters, recent surgery, or a weakened immune system. Molecular typing has revealed that hospital outbreaks can involve a single clone circulating within a facility, suggesting patient-to-patient or environment-to-patient transmission.¹⁴

Community-acquired infections caused by A. pittii are rare but increasingly documented. A case report from France described a 55-year-old person with no immune deficiency and no known risk factors who developed pneumonia with bloodstream infection caused by a wild-type (fully drug-susceptible) A. pittii strain during a heat wave.¹⁵ Another French case involved cavitary pneumonia in a 45-year-old woman with a history of smoking and lupus.¹⁶ Perhaps most alarming, a case in China described a 50-year-old man who developed septic shock and multiorgan failure from a community-acquired A. pittii strain that genomic sequencing confirmed to be hypervirulent.¹⁷

These community cases remain exceptions, not the rule. But they show that A. pittii is not exclusively a creature of the hospital ward, and extreme heat events may play a role by boosting bacterial growth in environmental water and soil. Clinicians outside ICU settings should keep A. pittii on their radar when dealing with unusual pneumonia presentations, especially in warm climates.

Environmental Reservoirs Beyond the Hospital

A. pittii is not confined to clinical settings. A broad genomic analysis found that food intended for human consumption, animals, and plants all serve as environmental sources of this organism.¹¹ Aquatic environments are another niche: a study of fish from wastewater-related waters identified A. pittii in about 10% of Acinetobacter isolates recovered from fish tissues.¹⁸

These environmental findings matter because they suggest a “One Health” dimension to A. pittii. If the organism circulates in food, water, and animals, then it can acquire resistance genes in agricultural settings (where antibiotics are also used) and carry them into hospitals via colonized patients. The fact that resistance and virulence genes sit largely on mobile elements in A. pittii’s accessory genome makes such cross-environment gene flow plausible. Surveillance programs that focus exclusively on hospital microbiology labs risk missing the broader picture.

Treatment Options

When A. pittii remains susceptible to carbapenems, treatment is relatively straightforward: a carbapenem such as meropenem or imipenem is the standard choice. The challenge arrives when the isolate is carbapenem-resistant, which is becoming more common. At that point, clinicians face the same difficult menu of options used for carbapenem-resistant A. baumannii.

The most significant recent development is sulbactam-durlobactam, a combination in which durlobactam protects sulbactam from being broken down by the bacterium’s enzymes. In a clinical trial focused on hospital-acquired and ventilator-associated pneumonia caused by the A. baumannii complex, the 28-day mortality was lower in the sulbactam-durlobactam group than in the colistin group (about 19% versus 32%), and both the clinical cure rate and the rate of bacterial clearance were significantly higher in the sulbactam-durlobactam arm.¹⁹ Based on those results, the U.S. FDA approved sulbactam-durlobactam for hospital-acquired pneumonia caused by the A. baumannii complex in 2023.

Laboratory testing of sulbactam-durlobactam against a global collection of Acb complex isolates showed that the combination inhibited over 98% of all tested strains at a preliminary susceptibility breakpoint, including strains that were resistant to carbapenems, colistin, and multiple other drug classes.²⁰ Because those collections include A. pittii, this drug represents a genuinely promising option for carbapenem-resistant A. pittii infections as well, though most clinical trial data were gathered from A. baumannii infections specifically.

Colistin remains a fallback for extensively resistant infections, but its kidney toxicity limits its use. High-dose ampicillin-sulbactam combinations without durlobactam have also been used historically, though their effectiveness drops once the isolate produces OXA carbapenemases that hydrolyze sulbactam itself. The arrival of durlobactam addresses that weakness directly.

How the Immune System Handles A. pittii

For patients with healthy immune systems, the body’s own defenses do much of the heavy lifting. Research examining how human immune cells interact with Acinetobacter species found that neutrophils (the white blood cells that arrive first at infection sites) were highly effective at engulfing A. pittii, with neutrophils observed to be packed full of bacteria after just a few hours of exposure. Macrophages, the other major phagocytic cell, showed less direct ingestion but became visibly activated in the presence of the bacteria.²¹ This helps explain why A. pittii infections are overwhelmingly a problem for people whose neutrophil counts or immune function are compromised. In an otherwise healthy person, the innate immune system often clears A. pittii before it can establish a foothold, which is part of why community-acquired cases in people without immune deficiency are so rare.

Infection Control in Hospitals

Controlling A. pittii in healthcare settings requires many of the same measures used against A. baumannii, but with particular attention to surface decontamination given A. pittii’s desiccation tolerance. Standard protocols include strict hand hygiene, contact precautions for colonized or infected patients, and environmental cleaning with hospital-grade disinfectants. The biofilm-forming capacity of A. pittii after drying out means that surfaces need to be not just wiped down but thoroughly cleaned: a quick pass with a damp cloth may leave viable organisms behind in a dried biofilm that reactivates with the next splash of moisture.

Antimicrobial stewardship is equally critical. The tendency of A. pittii to accumulate resistance genes on mobile genetic elements means that unnecessary antibiotic exposure in a hospital can select for resistant strains, which can then share those resistance genes with other species. Hospitals that track Acinetobacter infections at the species level, rather than grouping them all as “A. baumannii complex,” are better positioned to detect emerging resistance patterns and tailor empirical treatment accordingly.

Active surveillance cultures of high-risk patients on admission to the ICU have been used in some settings to catch colonization early and implement contact precautions before transmission occurs. Whether that approach is cost-effective depends on local rates of Acinetobacter colonization, but in facilities that have experienced outbreaks, it has proven valuable for breaking chains of transmission.

The Genomic Variability Problem

One of the reasons A. pittii resists easy generalization is the sheer diversity of its genome. The analysis of 384 genomes from 32 countries revealed that no two isolates are exactly alike. The core genome, the set of genes shared by essentially all A. pittii strains, accounts for only about a quarter to a third of any given isolate’s total genes.¹¹ Everything else is accessory: genes that drift in and out of the population on plasmids, transposons, and other mobile elements. That enormous accessory genome makes A. pittii a moving target. A strain circulating in a hospital in Europe may carry a completely different set of resistance and virulence genes than one in East Asia, even if both are the same species. This variability frustrates attempts to create a single risk profile for A. pittii and underscores the need for local surveillance data rather than global generalizations.

From a research standpoint, the large accessory genome also complicates efforts to identify what distinguishes hospital-adapted strains from environmental ones. The boundary between a harmless environmental organism and a dangerous hospital pathogen is not a fixed line in A. pittii’s genome but a sliding scale determined by whichever mobile elements happen to be on board. That fluidity is precisely why treating A. pittii as a predictable, low-risk cousin of A. baumannii would be a mistake.